Addressing the age-related needs of osteoporotic patients with strontium ranelate.
Osteoporotic fractures are associated with significant morbidity and mortality with an enormous impact on society and the lives of affected individuals. Age and menopause are the two main risk factors for osteoporosis, and women therefore need to be particularly concerned about bone loss at this time. In addition to suffering fracture-associated morbidity, women with prior fractures have an increased risk of future fractures. Young postmenopausal women who have experienced a fragility fracture therefore face a lifetime of fracture risk. The burden of fractures increases with advancing age, and bone mineral density declines, with women over the age of 80 years having the highest risk of fracture because of their high prevalence of osteoporosis and an increased likelihood of falls. A number of antiosteoporotic agents are available for the treatment of postmenopausal women including bisphosphonates, raloxifene, teriparatide, and strontium ranelate. For osteoporotic drugs to be beneficial in reducing the burden of fractures, they need to be effective against fracture in all age groups of postmenopausal women. With its dual mode of action, strontium ranelate is the first agent with proven early and sustained antifracture efficacy in all age groups including young postmenopausal women and those over 80 years. Evidence is now available to show that all women, including the elderly, can benefit from treatment to prevent further bone loss and restore lost bone to decrease the risk of further fractures. By implementing procedures to identify those at greatest risk and initiate safe and effective treatments, physicians can significantly improve patients' quality of life.
Boonen
S
S
Leuven University Centre for Metabolic Bone Diseases and Division of Geriatric Medicine, Leuven, Belgium. steven.boonen@med.kuleuven.be
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000453:epidemiology; D058866:Osteoporotic Fractures / Q000453:epidemiology / Q000517:prevention & control; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
Clin Ther. 2005 Jan;27(1):1-11
15763602
J Nutr Health Aging. 2008 May;12(5):335-46
18443717
Osteoporos Int. 2003;14 Suppl 3:S66-76
12730769
J Bone Miner Res. 2007 Mar;22(3):465-75
17144789
N Engl J Med. 1995 Mar 23;332(12):767-73
7862179
Curr Med Res Opin. 2008 Jun;24(6):1781-8
18489813
Osteoporos Int. 1997;7(4):390-406
9373575
Bone. 2010 Apr;46(4):1038-42
20026265
J Bone Miner Res. 2006 Apr;21(4):536-42
16598373
Osteoporos Int. 2000;11(7):556-61
11069188
Int J Clin Pract. 2007 Jun;61(6):963-71
17504359
Osteoporos Int. 1994;4 Suppl 1:59-65
8081062
Osteoporos Int. 2008 Apr;19(4):503-10
17929073
J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):744-51
17634322
J Orthop Trauma. 2003 Jan;17(1):53-6
12499968
BMJ. 2000 Feb 5;320(7231):341-6
10657327
N Engl J Med. 2004 Jan 29;350(5):459-68
14749454
Osteoporos Int. 2005 Mar;16(3):229-38
15618996
JAMA. 2007 Jan 24;297(4):387-94
17244835
Bone. 2004 Feb;34(2):362-7
14962815
Osteoporos Int. 2010 Feb;21(2):233-41
19436941
Osteoporos Int. 1997;7(5):407-13
9425497
Osteoporos Int. 1999;9(3):206-13
10450408
Ann Intern Med. 1998 May 15;128(10):793-800
9599190
Osteoporos Int. 1992 Nov;2(6):285-9
1421796
Arch Intern Med. 2003 Oct 13;163(18):2165-72
14557214
J Am Geriatr Soc. 2002 Oct;50(10):1644-50
12366617
J Bone Miner Res. 2006 Jul;21(7):1113-20
16813532
J Bone Miner Res. 2008 Nov;23(11):1832-41
18597630
Rheumatol Int. 2010 May;30(7):863-9
20035331
Rheum Dis Clin North Am. 2006 Nov;32(4):617-29
17288968
Ann Rheum Dis. 2008 Dec;67(12):1736-8
18713788
Osteoporos Int. 2005 May;16(5):447-55
15609073
Osteoporos Int. 2009 Oct;20(10):1633-50
19421703
J Am Geriatr Soc. 2004 Nov;52(11):1832-9
15507059
Bone. 2004 Aug;35(2):375-82
15268886
J Clin Endocrinol Metab. 2005 May;90(5):2816-22
15728210
Lancet. 2002 May 18;359(9319):1761-7
12049882
Bone. 1995 Nov;17(5 Suppl):505S-511S
8573428
J Am Geriatr Soc. 2006 May;54(5):782-9
16696744
Osteoporos Int. 2004 Nov;15(11):897-902
15490120
Curr Med Res Opin. 2009 Oct;25(10):2373-87
19650751
J Bone Miner Res. 1997 Nov;12(11):1761-8
9383679
Curr Opin Rheumatol. 2006 Jun;18 Suppl 1:S11-5
16735840
Arthritis Res. 2000;2(6):441-5
11094456
Bone. 2001 Dec;29(6):517-22
11728921
J Bone Miner Res. 1997 Jan;12(1):16-23
9240721
Osteoporos Int. 2008 Apr;19(4):385-97
18292978